130 related articles for article (PubMed ID: 38588464)
21. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity.
Cai R; Zhang X; Wang H; Cui T; Halmos G; Sha W; He J; Popovics P; Vidaurre I; Zhang C; Mirsaeidi M; Schally AV
Peptides; 2022 Apr; 150():170716. PubMed ID: 34952135
[TBL] [Abstract][Full Text] [Related]
22. Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice.
Recinella L; Chiavaroli A; Orlando G; Ferrante C; Marconi GD; Gesmundo I; Granata R; Cai R; Sha W; Schally AV; Brunetti L; Leone S
Sci Rep; 2020 Jan; 10(1):732. PubMed ID: 31959947
[TBL] [Abstract][Full Text] [Related]
23. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
[TBL] [Abstract][Full Text] [Related]
24. Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling.
Gan J; Ke X; Jiang J; Dong H; Yao Z; Lin Y; Lin W; Wu X; Yan S; Zhuang Y; Chu WK; Cai R; Zhang X; Cheung HS; Block NL; Pang CP; Schally AV; Zhang H
Proc Natl Acad Sci U S A; 2016 Dec; 113(51):14745-14750. PubMed ID: 27930339
[TBL] [Abstract][Full Text] [Related]
25. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
Hohla F; Buchholz S; Schally AV; Seitz S; Rick FG; Szalontay L; Varga JL; Zarandi M; Halmos G; Vidaurre I; Krishan A; Kurtoglu M; Chandna S; Aigner E; Datz C
Cell Cycle; 2009 Oct; 8(19):3149-56. PubMed ID: 19755849
[TBL] [Abstract][Full Text] [Related]
26. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
Rick FG; Schally AV; Block NL; Nadji M; Szepeshazi K; Zarandi M; Vidaurre I; Perez R; Halmos G; Szalontay L
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3755-60. PubMed ID: 21321192
[TBL] [Abstract][Full Text] [Related]
27. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.
Rick FG; Seitz S; Schally AV; Szalontay L; Krishan A; Datz C; Stadlmayr A; Buchholz S; Block NL; Hohla F
Cell Cycle; 2012 Nov; 11(22):4203-10. PubMed ID: 23095641
[TBL] [Abstract][Full Text] [Related]
28. Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2.
Catanuto P; Tashiro J; Rick FG; Sanchez P; Solorzano CC; Glassberg MK; Block NL; Lew JI; Elliot SJ; Schally AV
Horm Cancer; 2015 Jun; 6(2-3):100-6. PubMed ID: 25752763
[TBL] [Abstract][Full Text] [Related]
29. Growth hormone-releasing hormone antagonistic analog MIA-690 stimulates food intake in mice.
Recinella L; Chiavaroli A; Orlando G; Ferrante C; Gesmundo I; Granata R; Cai R; Sha W; Schally AV; Brunetti L; Leone S
Peptides; 2021 Aug; 142():170582. PubMed ID: 34051291
[TBL] [Abstract][Full Text] [Related]
30. Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
Muñoz-Moreno L; Schally AV; Prieto JC; Carmena MJ; Bajo AM
Prostate; 2018 Sep; 78(12):915-926. PubMed ID: 29748961
[TBL] [Abstract][Full Text] [Related]
31. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
[TBL] [Abstract][Full Text] [Related]
32. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells.
Ziegler CG; Ullrich M; Schally AV; Bergmann R; Pietzsch J; Gebauer L; Gondek K; Qin N; Pacak K; Ehrhart-Bornstein M; Eisenhofer G; Bornstein SR
Mol Cell Endocrinol; 2013 May; 371(1-2):189-94. PubMed ID: 23267837
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
Engel JB; Keller G; Schally AV; Toller GL; Groot K; Havt A; Armatis P; Zarandi M; Varga JL; Halmos G
J Clin Endocrinol Metab; 2005 Jun; 90(6):3614-21. PubMed ID: 15784701
[TBL] [Abstract][Full Text] [Related]
35. Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.
Wu HM; Huang HY; Schally AV; Chao A; Chou HH; Leung PC; Wang HS
Oncotarget; 2017 Jan; 8(3):4410-4421. PubMed ID: 28032599
[TBL] [Abstract][Full Text] [Related]
36. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Prieto JC; Bajo AM
Invest New Drugs; 2014 Oct; 32(5):871-82. PubMed ID: 25000999
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
[TBL] [Abstract][Full Text] [Related]
38. Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target.
Xiong X; Ke X; Wang L; Yao Z; Guo Y; Zhang X; Chen Y; Pang CP; Schally AV; Zhang H
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6726-6732. PubMed ID: 32156725
[TBL] [Abstract][Full Text] [Related]
39. GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro.
Bellyei S; Schally AV; Zarandi M; Varga JL; Vidaurre I; Pozsgai E
Cancer Lett; 2010 Jul; 293(1):31-40. PubMed ID: 20064686
[TBL] [Abstract][Full Text] [Related]
40. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression.
Kweon SH; Song JH; Kim TS
Biochem Biophys Res Commun; 2010 Apr; 395(1):104-10. PubMed ID: 20350534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
